Researchers at Stanford Medicine have made significant strides in vaccine development, unveiling a universal vaccine candidate that shows promise in protecting against a diverse array of respiratory viruses, bacteria, and allergens in mice. This innovative vaccine, which is administered intranasally, offers sustained protection in the lungs for several months, marking a departure from traditional vaccination methods.
Led by Bali Pulendran, PhD, the team demonstrated that this new vaccine could shield vaccinated mice from notable respiratory threats, including SARS-CoV-2 and other coronaviruses, as well as common hospital-acquired infections like Staphylococcus aureus and Acinetobacter baumannii. The findings were published in the journal Science in a study titled “Mucosal vaccination in mice provides protection from diverse respiratory threats.”
The vaccine’s design integrates both innate and adaptive immunity, creating a feedback loop that enhances the immune response. Pulendran emphasized the potential transformative impact of this vaccine if it proves safe and effective in humans, stating, “… simplifying seasonal vaccination and improving readiness for emerging respiratory threats.”
Addressing the Limitations of Traditional Vaccines
Traditional vaccines have relied on antigen specificity to prepare the immune system for specific pathogens. This approach, while effective, often falls short when viruses mutate or new pathogens emerge. Pulendran pointed out the pressing need for a broadly protective vaccine, stating, “… many pathogens are able to quickly mutate,” highlighting the limitations of current annual COVID-19 boosters and flu shots.
The research team’s novel vaccine does not attempt to mimic any part of a pathogen. Instead, it replicates the signals that immune cells use to communicate during infections. This approach contrasts sharply with the long-standing “antigen-specific” paradigm in vaccinology, which has been the guiding principle for over two centuries. Pulendran remarked that the vaccine strategy aims to recreate essential immune communication signals in the lungs, maintaining a heightened protective state while engaging adaptive immunity.
Innovative Mechanisms and Promising Results
Previous research, including studies on the BCG tuberculosis vaccine, has suggested that innate immunity can provide extended protection under certain conditions. Pulendran’s team recently demonstrated that T cells recruited to the lungs can sustain the activation of innate immune cells, extending their protective response from days to several months.
In their preclinical studies, the researchers found that their new vaccine, designated GLA-3M-052-LS+OVA, effectively mimics T cell signals that stimulate innate immune cells. After administering the vaccine to mice via nasal drops, some receiving multiple doses, the results were promising. Mice that received three doses exhibited protection against SARS-CoV-2 for at least three months, while unvaccinated controls suffered significant weight loss and lung inflammation.
The dual-action nature of the vaccine lowers viral loads in the lungs significantly and prepares the adaptive immune system to respond rapidly. “The lung immune system can launch typical adaptive responses—virus-specific T cells and antibodies—in as little as three days,” Pulendran explained, a remarkable reduction compared to the typical two-week response time in unvaccinated mice.
The researchers expanded their investigation to include protection against bacterial infections. Results indicated that vaccinated mice were also shielded from bacteria like Staphylococcus aureus for approximately three months. Furthermore, when exposed to allergens such as house dust mite proteins, vaccinated mice maintained clear airways, illustrating the vaccine’s potential to prevent allergic asthma.
Looking ahead, Pulendran expressed hope that this universal vaccine could eventually replace the need for multiple vaccinations against seasonal respiratory infections, paving the way for enhanced pandemic preparedness. The research team aims to advance their findings into human trials, beginning with a Phase I safety trial. They anticipate that two doses of the nasal spray would suffice for human protection, similar to the effective doses observed in mice.
As the research progresses, the team is exploring various vaccine candidates and formulations to identify the most promising option for future development. The ultimate goal is to create a vaccine that could be widely administered, providing broad protection against a spectrum of respiratory pathogens and significantly transforming medical practice.
